☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Regulatory
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
Weekly Snapshot
PharmaShots Weekly Snapshots (July 01 – July 05, 2024)
July 5, 2024
Zhejiang Doer Biologics Concludes Patient Recruitment in P-Ib/IIa Study of DR10624 Among Obese Individuals
July 5, 2024
Zhejiang Doer Biologics Concludes Patient Recruitment in P-Ib/IIa Study of DR10624 Among Obese Individuals
July 5, 2024
Pharma
Pendopharm Collaborates with Ascendis Pharma to Commercialize TransCon PTH for Treating Hypoparathyroidism in Canada
July 5, 2024
Pendopharm Collaborates with Ascendis Pharma to Commercialize TransCon PTH for Treating Hypoparathyroidism in Canada
July 5, 2024
Eleva’s CPV-104 Gains EC’s Orphan Drug Designation to Treat C3 Glomerulopathy (C3G)
July 5, 2024
ThoughtSpot
Lasers In Dentistry: Hard-Tissue Applications
July 4, 2024
Medigene Receives Chinese Patent for MDG1015 to Treat Various Solid Tumors
July 4, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
First Name
Last Name
Daily Newsletter
Weekly Newsletter
I agree to the privacy policy and terms.(
Link
)
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
